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ABSTRACT
Background: Agitation is common across neuropsychiatric disorders and contributes to disability,
institutionalization, and diminished quality of life for patients and their caregivers. There is no consensus
definition of agitation and no widespread agreement on what elements should be included in the syndrome.
The International Psychogeriatric Association formed an Agitation Definition Work Group (ADWG) to
develop a provisional consensus definition of agitation in patients with cognitive disorders that can be
applied in epidemiologic, non-interventional clinical, pharmacologic, non-pharmacologic interventional, and
neurobiological studies. A consensus definition will facilitate communication and cross-study comparison and
may have regulatory applications in drug development programs.
Methods: The ADWG developed a transparent process using a combination of electronic, face-to-face, and
survey-based strategies to develop a consensus based on agreement of a majority of participants. Nine-hundred
twenty-eight respondents participated in the different phases of the process.
Results: Agitation was defined broadly as: (1) occurring in patients with a cognitive impairment or dementia
syndrome; (2) exhibiting behavior consistent with emotional distress; (3) manifesting excessive motor activity,
verbal aggression, or physical aggression; and (4) evidencing behaviors that cause excess disability and are
not solely attributable to another disorder (psychiatric, medical, or substance-related). A majority of the
respondents rated all surveyed elements of the definition as “strongly agree” or “somewhat agree” (68–88%
across elements). A majority of the respondents agreed that the definition is appropriate for clinical and
research applications.
Conclusions: A provisional consensus definition of agitation has been developed. This definition can be used
to advance interventional and non-interventional research of agitation in patients with cognitive impairment.
Key words: Alzheimer’s disease, agitation, cognitive impairment, aggression, International Psychogeriatric Association, Food and Drug
Administration, clinical trials, intervention, epidemiology
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Introduction
Agitation is a common clinical manifestation
of many neuropsychiatric disorders. It is a
frequentmanifestation of Alzheimer’s disease (AD),
frontotemporal dementia (FTD), dementia with
Lewy bodies (DLB), and other dementia syndromes
(Ballard and Corbett, 2010; Manoochehri and
Huey, 2012; Bruns and Josephs, 2013). It occurs
in schizophrenia, bipolar illness, and depression
(Gonzalez et al., 2013; Swann, 2013). While
agitation may include aggressive behaviors, it is
not identical to aggression, and agitation can
occur without aggression (e.g. pacing, rocking,
repetitious mannerisms). Agitation can precipitate
institutionalization (Okura et al., 2011), diminishes
the quality of life of patients and caregivers
(Khoo et al., 2013), and, when severe, may
require treatment with medications (Herrmann and
Lanctôt, 2007). There is an emerging biology
of agitation, and frontal lobe dysfunction is
implicated in both clinical and neuroimaging
studies (Senanarong et al. 2004; Bruen et al., 2008).
Treatment of agitation – both pharmacologic and
non-pharmacologic – is an unmet need in the care
of patients with cognitive impairment (Herrmann
and Lanctôt, 2007; Gitlin et al., 2012).
In spite of the framework of studies that have
begun to increase understanding of agitation, there
is no commonly accepted consensus description
of this common clinical phenomenon (Laughren,
2001). Lay definitions of agitation are non-specific
and include states of excitement, disturbance,
or worry. A consensus definition of agitation
applicable in the setting of cognitive impairment
would facilitate a wide spectrum of research,
including pharmacologic and non-pharmacologic
intervention studies, epidemiologic investigations
of agitation, clinical studies, and research on
the neurobiology of this behavior. A definition
would also provide a common framework for
diagnostic nomenclatures such as the International
Classification of Diseases and Related Health
Problems (ICD; (World Health Organization,
2014) and the Diagnostic and Statistical Manual
of Mental Disorders (DSM; (American Psychiatric
Association, 2013). In addition, clinically relevant
definitions have important regulatory applications;
when agents possibly appropriate for the treatment
of agitation are presented to the Food and
Drug Administration (FDA), European Medicines
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Agency (EMA), or other licensing authorities,
the treatment indication must be defined using
language useful to clinicians caring for patients with
the condition. Without a consensus definition, it is
difficult to compare studies or to know what range
of behaviors were included in a study of “agitation.”
Rating scales such as the Cohen-Mansfield
Agitation Inventory (Cohen-Mansfield et al., 1989),
Neuropsychiatric Inventory (NPI; Cummings et al.,
1994), or Behavioral Pathology in Alzheimer’s
Disease (BEHAVE-AD; Reisberg et al., 1987; De
Deyn andWirshing, 2001) are often used to identify
patients for clinical trials of anti-agitation agents
and to measure the clinical symptoms in other
descriptive and intervention studies. Rating scales,
however, are not definitions; rather, they are means
of measuring the frequency or severity of symptoms.
Most clinicians do not use rating scales for routine
care of patients. To assist in defining populations
for clinical care and research, a definition that is not
dependent on a particular rating scale is needed.
The International Psychogeriatric Association
(IPA) has an established leadership role in the field
of geriatric behavioral health, including agitation,
and has led initiatives involved with this topic
(Finkel et al., 1996; Reisberg et al., 1997; Draper,
1999; Finkel, 2000). To advance the study of
agitation by establishing a consensus definition, the
IPA formed anAgitationDefinitionWorkingGroup
(ADWG) to produce a provisional consensus
definition of agitation. The ADWG conducted
a broadly inclusive process, involving the IPA
and its affiliate members, employing electronic
means of participant engagement, holding a face-
to-face meeting with international representation,
and using survey-based methods. The ADWG
was made up of the IPA leadership and other
stakeholders interested in the neuropsychiatric
aspects of AD and other disorders. The ADWG
implemented a transparent process that included
nearly 1,000 survey respondents and engaged the
memberships of the IPA, IPA affiliates, and other
organizations involved in the care and research of
neuropsychiatric disorders in patients with cognitive
impairment. Here the process is described, the
definition is presented, and the elements of the
definition are discussed.
Methods
Consensus-building process
INITIAL FORMULATION
The literature was reviewed (by Jeffrey Cummings),
past definitions of agitation identified, and common
elements of the definitions reviewed. A preliminary
survey of these definitions and elements to
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Table 1. Consensus provisional deﬁnition of agitation in cognitive disorders
A. The patient meets criteria for a cognitive impairment or dementia syndrome (e.g. AD, FTD, DLB, vascular dementia,
other dementias, a pre-dementia cognitive impairment syndrome such as mild cognitive impairment or other cognitive
disorder).
B. The patient exhibits at least one of the following behaviors that are associated with observed or inferred evidence of
emotional distress (e.g. rapid changes in mood, irritability, outbursts). The behavior has been persistent or frequently
recurrent for a minimum of two weeks’ and represents a change from the patient’s usual behavior.
(a) Excessive motor activity (examples include: pacing, rocking, gesturing, pointing fingers, restlessness, performing
repetitious mannerisms).
(b) Verbal aggression (e.g. yelling, speaking in an excessively loud voice, using profanity, screaming, shouting).
(c) Physical aggression (e.g. grabbing, shoving, pushing, resisting, hitting others, kicking objects or people, scratching,
biting, throwing objects, hitting self, slamming doors, tearing things, and destroying property).
C. Behaviors are severe enough to produce excess disability, which in the clinician’s opinion is beyond that due to the
cognitive impairment and including at least one of the following:
(a) Significant impairment in interpersonal relationships.
(b) Significant impairment in other aspects of social functioning.
(c) Significant impairment in ability to perform or participate in daily living activities.
D. While co-morbid conditions may be present, the agitation is not attributable solely to another psychiatric disorder,
suboptimal care conditions, medical condition, or the physiological effects of a substance.
be considered for inclusion was developed and
presented to the IPA leadership.
SURVEY 1
The ADWG was formed to guide this project.
The ADWG reviewed the proposed survey, adding
or deleting elements to enhance the focus and
clarity of the questions. The revised survey was
sent electronically to the IPA membership and
affiliate members (organizations that share the
mission of advancing clinical practice, research,
and education to improve the mental health of
the elderly). The survey collected demographic
information on the respondents, determined the
preferences among five definitions of agitation
used in the literature (Kong, 2005), asked if the
definition should be limited to cognitive impairment
syndromes, established key behavioral elements
to be included in a definition, and interrogated
whether the respondents considered agitation and
anxiety to be the same and whether agitation and
aggression are the same.
INTERNATIONAL EXPERT CONSENSUS
MEETING
Following completion and analysis of the first
survey, an international expert consensus meeting
was held to develop a draft definition based on
a review of the literature and information derived
from the survey. The members of the ADWG
present at the meeting include the authors of
this paper. In this meeting a draft definition
was developed that represented a consensus of
those present. Following the expert meeting, a
preliminary draft of the definition was developed
and circulated to all members of the ADWG.
Through multiple electronic exchanges a final
consensus was reached (Table 1). Not all aspects
of the consensus definition were unanimously
endorsed by all participants but a majority of
stakeholders agreed on the elements.
To develop further consensus beyond the
ADWG, other key stakeholder groups received
the provisional definition for comments, including
the members of the Neuropsychiatric Syndrome
Professional Interest Area of ISTAART (Geda et al.,
2013) comprising thought leaders in the area of
neuropsychiatric aspects of AD.
SURVEY 2
Once an expert consensus from the ADWG was
achieved, the IPA and affiliate members were re-
contacted to provide additional input into the
definition and its acceptability for clinical and
research studies, including prospective validation
investigations. Six thousand emails were sent; there
were 350 respondents (7%) in this phase of the
consensus development process.
REPORT PREPARATION
Once the second survey was complete, this report
containing a description of the consensus process,
the definition, and the elements of the definition was
prepared (Jeffrey Cummings) and circulated among
the ADWG members. Agreement was reached
on the text describing the provisional definition
and the manuscript was submitted to International
Psychogeriatrics for review.
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Table 2. Five proposed deﬁnitions of agitation in dementia and the number of respondents who ranked each
of them as the best or the second-best deﬁnition
DEFINITION
PERCENTAGE OF
RESPONDENTS
WHO RANKED THE
DEFINITION AS THE
BEST
PERCENTAGE OF
RESPONDENTS
WHO RANKED THE
DEFINITION AS THE
SECOND BEST
......................................................................................................................................................................................................................................................................................................................
The patient has periods when he refuses to cooperate,
won’t let people help, or is hard to handle.
4 4
Excessive motor activity associated with a feeling of inner
tension. The activity is usually non-productive and
repetitious and consists of such behavior as inability to sit
still, pacing, wringing of hands, and pulling at clothes.
31 19
Inappropriate verbal, vocal, or motor activity that is not
explained by needs or confusion per se. It includes
behaviors such as aimless wandering, pacing, cursing,
screaming, biting, and fighting.
22 38
Vocal or motor behavior that is either disruptive, unsafe, or
interferes with the delivery of care in a particular
environment. It included four behavioral areas such as
vocalization, motor disturbances, aggressiveness, and
resisting care.
34 26
Those observed patient behaviors that communicate to
others that the patient is experiencing an unpleasant state
of excitement and which remain after interventions to
reduce internal or external stimuli by managing
resistiveness, alleviating aversive physical signs, and
decreasing sources of accumulated stress have been
carried out.
9 12
Results
Survey 1
Six thousand emails were sent; 557 individuals
responded. The response rate from IPA members
was 30.1%. Many members of the IPA and
affiliate organizations are involved predominantly
with mood disorders, psychosis, or other non-
dementia aspects of geriatric psychiatry. Of
the 557 respondents, 382 were physicians,
including 292 psychiatrists. Other professional
disciplines providing responses included nurses
(57), psychologists (50), occupational therapists
(13), social workers (14), and others/no responses
(41). Three hundred eighty-eight (70%) of the
respondents had been in practice for more than ten
years.
This initial survey provided valuable insights
from those involved in the care of agitated patients,
and key elements of the definition were identified.
Table 2 shows the responses to five existing
definitions of agitation (Kong, 2005). Three of the
definitions had relatively high acceptability (22–
34% rating as the “best definition”).
The ADWG surveyed essential elements of
the definition of agitation. The percentage of
respondents identifying specific adjectives as key
Table 3. Proposed elements of a deﬁnition of
agitation and the percentage of respondents
endorsing that item as an essential element of a
deﬁnition of agitation
ELEMENT
PERCENTAGE OF RESPONDENTS
ENDORSING THE ELEMENTS AS A
KEY COMPONENT OF A
DEFINITION OF AGITATION
......................................................................................................................................................
Excessive 71
Inappropriate 54
Repetitive 46
Observable 64
Dangerous 24
Disruptive 56
behavioral elements of the definition included:
excessive (71%), inappropriate (54%), repetitive
(46%), observable (64%), dangerous (24%), and
disruptive (56%) (Table 3).
Of the items listed as possible behaviors to be
included in a definition of agitation, the following
were endorsed by at least 50% of the respondents:
pacing, aimless wandering, verbal aggression,
constant unwarranted requests for attention or
help, hitting others, hitting self, pushing people,
throwing things, general restlessness, screaming,
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resistiveness, hurting self, hurting others, tearing
things or destroying property, shouting, and kicking
furniture (Table 4). This information guided the
elements included in the definition by the ADWG.
When queried as to whether agitation and
anxiety were the same, overlapping, or distinct
concepts, most of the respondents found them to
be overlapping (0.3%, 61%, and 37% respectively).
When asked whether agitation and aggression are
the same, overlapping, or distinct, 0.8%, 66%, and
32% endorsed each option.
Survey 2
Table 5 lists the questions of the survey regarding
the definition developed by the ADWG and the
responses of the participants. All elements of
the definition surveyed were rated as “strongly
agree” or “somewhat agree” by a majority of
the respondents (ranging from 68.2% for “the
exclusion criterion is clear” to 88.8% for “the
physical aggression components are captured
appropriately in the definition”). A majority agreed
(strongly or somewhat) that the definition is
appropriate for research application. For non-
interventional descriptive clinical research, 44%
strongly agreed and 33.7% somewhat agreed
with the appropriateness of the definition (77.7%
agreed); for pharmacologic interventional clinical
research, 43.7% strongly agreed and 31.7%
somewhat agreed (75.4% agreed); and for clinical
trials 39.2% and 36% agreed strongly and
somewhat respectively (75.2% agreed).
When queried whether the definition should be
limited to cognitive impairment syndromes – the
approach taken by the ADWG – 67.4% said “yes.”
Discussion
Elements of the consensus definition
The provisional consensus definition uses the
DSM style for defining a disorder as one
that produces disability (American Psychiatric
Association, 2013). The definition is limited
to patients with cognitive impairment, requires
evidence of emotional distress, requires one of the
three observable types of behavior (excessive motor
activity, verbal aggression, or physical aggression),
specifies that the behavior causes excess disability,
and notes that the behaviors cannot be solely
attributable to a suboptimal care environment or
another disorder such as psychiatric illness, medical
illness, or effects of a substance.
PROVISIONAL CONSENSUS DEFINITION
The definition is labeled as “provisional” because
it may evolve as it is subjected to prospective
Table 4. Behaviors that survey respondents
indicated should be included in a deﬁnition of
agitation
ITEM
PERCENTAGE OF
RESPONDENTS WHO
THOUGHT THE ITEM
BELONGED TO THE
DEFINITION OF
AGITATION
......................................................................................................................................................
Pacing 68
Aimless wandering 52
Spitting at meals 29
Spitting at people 40
Cursing 42
Verbal aggression 71
Constant unwarranted
requests for attention or
help
53
Repetitive questions 35
Repetitive sentences 31
Hitting others 58
Hitting self 57
Grabbing people 48
Pushing people 54
Throwing things 56
General restlessness 80
Screaming 63
Biting 49
Scratching 48
Trying to get to a different
place (e.g. out of the room
or building)
48
Intentional falling 16
Complaining 20
Negativism 21
Resistiveness 54
Eating/drinking
inappropriate substances
15
Hurting self 54
Hurting others 53
Handling things
inappropriately
26
Hiding things 11
Hoarding things 12
Tearing things or destroying
property
62
Performing repetitious
mannerisms
45
Making verbal sexual
advances
23
Making physical sexual
advances
24
Making strange noises (weird
laugher or crying)
38
Stubbornness 17
Shouting 62
Slamming doors intentionally 46
Kicking furniture 52
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Table 5. Questions of survey 2 exploring the acceptability of the draft deﬁnition and the percentage of
participants who responded as strongly agree or somewhat agree
SURVEY QUESTION
PERCENTAGE OF
RESPONDENTS WHO
STRONGLY AGREE
PERCENTAGE OF
RESPONDENTS WHO
SOMEWHAT AGREE
......................................................................................................................................................................................................................................................................................................................
The definition captures what I mean when I use the term
“agitation” to describe one of my patients.
50.8 35.1
The inclusion criteria – A, B, C – are sufficiently clear for
clinical application.
51.7 31.7
The inclusion criteria – A, B, C – are sufficiently clear for
research application.
35.7 37.7
The exclusion criterion – D – is sufficiently clear for clinical
application.
38.5 36.8
The exclusion criterion – D – is sufficiently clear for research
application.
26.0 42.2
The subjective aspects of the syndrome are captured
appropriately – observed or inferred evidence of emotional
distress (e.g. rapid changes in mood, irritability, outbursts).
The behavior has been sustained or persistent for a
minimum of two weeks in duration and represents a change
from the person’s usual behavior.
42.8 35.4
The physical aggression aspects of the syndrome are captured
appropriately – grabbing, shoving, pushing, resisting, hitting
others, kicking objects or people, scratching, biting,
throwing objects, hitting self, slamming doors, tearing
things, and destroying property.
65.7 23.1
The verbal aspects of the syndrome are captured
appropriately – yelling, speaking in an excessively loud
voice, using profanity, screaming, shouting.
59.7 28.2
The definition is appropriate as a means of identifying
patients for non-interventional descriptive clinical research.
44.0 33.7
The definition is appropriate as a means of identifying patients
for non-pharmacologic interventional clinical research.
43.7 31.7
The definition is appropriate as a means of identifying
patients for clinical trials.
36.2 36
The definition is appropriate as a foundation for validation
studies of its sensitivity and specificity.
39.4 36.2
validation. It represents an important starting point
in a dynamic dialogue that will evolve with clinical
application, research, and review. Validation studies
are expected to show that some elements are better
suited to clinical and research applications than
others.
The definition was labeled as a “consensus”
because a majority of stakeholders involved in
the process concurred with the current definition.
Not all elements were unanimously endorsed; a
consensus was achieved on all aspects of the
definition.
LIMITATION TO SYNDROMES WITH
COGNITIVE IMPAIRMENT
Agitation occurs in many disorders and is not
limited to conditions with cognitive impairment
(Ballard and Corbett, 2010; Manoochehri and
Huey, 2012; Bruns and Josephs, 2013; Gonzalez
et al., 2013; Swann, 2013). The ADWG and
the participating members of the surveys favored
limiting the definition to disorders with cognitive
impairment. Sixty-seven percent of Survey 2
respondents agreed with this approach.
There are currently separate definitions for
psychosis of AD and psychosis in schizophrenia
even though they have shared elements such as
delusions and hallucinations (Jeste and Finkel,
2000); similarly there are definitions of major
depression and depression in AD that are
overlapping but not identical (Olin et al., 2003).
Similar considerations may apply to agitation,
and we chose to develop a definition explicitly
for patients with cognitive impairment. Further
research may lead to modifications of this approach.
The FDA has expressed concern about “pseudo-
specificity” of syndromes that are artificially
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assigned to one disorder when they represent
general syndromes for which drugs are already
approved (Cummings and Jeste, 2007), and the
ADWG wished to avoid constructing a definition
that might raise this issue. Our definition applies
specifically to the type of agitation observed in
patients with cognitive impairment based on the
unique relationships of agitation with aspects of
cognition (Senanarong et al., 2004); a distinct
pathophysiology (Bruen et al., 2008; Trzepacz
et al., 2013); and possibly a differential response
to treatment compared with syndromes such as
psychosis of AD (Schneider et al., 2006).
SUBJECTIVE ASPECT
The definition requires that there be observed or
inferred evidence of emotional distress. Examples
of behaviors indicative of emotional distress
are provided, including rapid changes in mood,
irritability, or emotional outbursts. The ADWG
required this subjective element because agitation
as conceived by the panel includes the concept
that the patient is upset or distressed, and the
agitated behavior is an expression of this emotional
state. A person could exhibit purposeful aggression
with behaviors overlapping with the definition but
would not be classified as “agitated” if there was no
associated distress. It is also important that patients
not be treated when their behavior is upsetting to
someone else (a family member or caregiver) but
not to the patient. Requiring the subjective element
of the definition makes this less likely. It is not
possible to directly observe emotional states, and
they must be inferred from observable behaviors.
In all, 78.2% of the Survey 2 respondents strongly
(42.8%) or somewhat (35.4%) agreed that this
aspect of agitation was captured appropriately by
the proposed definition.
SUSTAINED
A single episode or short-lived period of behavioral
change would not meet the definition for agitation
developed by the ADWG. The definition applies
to a chronic or at least long-lasting state that
has been sustained, persisted, or been frequently
recurrent for at least two weeks. This aspect of
the definition will assist with intervention studies
(pharmacologic and non-pharmacologic) where
interventional groups are compared and sustained
behavioral changes are required to see a difference
in the study outcomes.
CHANGE FROM PREVIOUS BEHAVIOR
The ADWG limited the definition of agitation
to patients with cognitive impairment. Behaviors
that preceded the onset of the associated cognitive
disorder would not be included in this definition.
This aspect of the consensus definition is similar to
the precedent adapted in the definition of psychosis
of AD (Jeste and Finkel, 2000).
OBSERVABLE BEHAVIORS
The patient must have at least one type of
observable agitated behavior. The behaviors can
include excessive motor activity (such as pacing,
rocking, gesturing, pointing fingers, restlessness,
performing repetitious mannerisms), verbal aggres-
sion (e.g. yelling, speaking in an excessively loud
voice, using profanity, screaming, shouting), or
physical aggression (e.g. grabbing, shoving, pushing,
resisting, hitting others, kicking objects or people,
scratching, biting, throwing objects, hitting self,
slamming doors, tearing things, and destroying
property). These behaviors are the core aspects of
the agitation syndrome; they reflect the behaviors
endorsed in Survey 1 as comprising agitation. The
ADWG recognized that agitated patients exhibit
different repertoires of behaviors and that, in
the presence of emotional distress, any of the
behaviors described would fulfill this criterion of
the definition. Clinician judgment is not prohibited
by the definition and behaviors other than those
listed may be present in agitated patients. In
all, 88.8% of the Survey 2 respondents strongly
(65.7%) or somewhat (23.1%) agreed that the
proposed definition appropriately captured the
physical aggression aspects of agitation, and 87.9%
strongly (59.7%) or somewhat (28.2%) agreed
regarding the verbal aspects of agitation.
EXCESS DISABILITY
A disorder is defined as producing disability
(American Psychiatric Association, 2013), and the
ADWG incorporated this aspect of the definition
as a measure of the clinical meaningfulness
of the behavior. If the behavior produces no
disability for the individual in terms of interpersonal
relationships, social function, or impact on daily
living activities, then it would not meet this criterion
of the definition. The disability must be more than
can be attributed solely to the cognitive impairment
syndrome. Clinician judgment will be required to
make this determination.
NECESSARY EXCLUSIONS
Agitation has many possible causes and is seen
across a broad range of neuropsychiatric illnesses
(Ballard and Corbett, 2010; Manoochehri and
Huey, 2012; Bruns and Josephs, 2013; Gonzalez
et al., 2013; Swann, 2013). The definition proffered
by the ADWG requires the presence of an
underlying cognitive impairment syndrome such as
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AD, FTD, DLB, or a prodromal dementia state.
In some cases, patients with these disorders may
have other psychiatric illness, medical illness, use
substances, or be in suboptimal care environments
that can cause agitated behaviors. The ADWG
definition requires that the agitation not be
attributable solely to one of these co-existing
conditions. Clinician judgment may be required to
make this determination. The exclusion aspects of
the definition had some of the lowest endorsements
on Survey 2 as 38.5% strongly agreed and 36.8%
somewhat agreed that the exclusions were adequate
for clinical application; 26% strongly agreed and
42.2% somewhat agreed that the exclusions were
adequate for research application.
Comment on the definition
The ADWG definition of agitation with cognitive
impairment is broad and assumes that agitation
is a syndrome and not a response to another
disorder. An alternative approach is to define
an “agitation with psychosis,” “agitation with
depression,” etc. An extensive literature establishes
that agitation can be seen in the absence
of concomitant psychopathology; neuroimaging
studies suggest unique regional dysfunction that
is distinct from other disorders (Bruen et al.,
2008; Trzepacz et al., 2013); and clinical trials
demonstrate that the pharmacologic response of
agitation may differ from that of other types of
behavioral disturbances (Schneider et al., 2006).
Therapies have been approved for agitation in
multiple psychiatric settings (e.g. aripiprazole for
acute treatment of agitation with schizophrenia
or bipolar I disorder), setting a precedent for
viewing agitation as a distinct syndrome. While
no drug has been approved for agitation per se
(i.e. without aggression, depression, or psychosis),
several psychosocial interventions have shown
benefit in reducing agitated behavior (Low et al.,
2013). The ADWG favored defining agitation as a
distinct clinically identifiable syndrome.
Using a syndromal definition of clinical phenom-
ena within neurologic disorders has a precedent
in the identification of pseudo-bulbar affect (PBA)
and the approval of dextromethorphan/quinidine
for PBA across neurologic disorders after having
demonstrated efficacy in amyotrophic lateral
sclerosis and multiple sclerosis. A similar strategy
of showing efficacy for anti-agitation agents across
several disorders could be adopted in anti-agitation
drug development programs.
The relationship of agitation to aggression
sparked discussion. These are overlapping but
not identical concepts (Cohen-Mansfield and
Mintzer, 2005). Agitation can occur in the
absence of aggression, and predatory aggression
can occur without agitation; it is unlikely
that aggression occurs without agitation in the
cognitive impairment syndromes described by
the ADWG. Sixty-six percent of the survey
respondents consider agitation and aggression
as overlapping concepts; 32% consider them to
be distinct. Aggression may be a more severe
form of agitation or it may occur in differing
biological or psychological circumstances. The
comparative response profiles to pharmacologic
or non-pharmacologic interventions of agitation
with and without aggression have not been
comprehensively explicated. There is currently
insufficient evidence to conclude that agents or
interventions used for aggressive agitation would
necessarily work or be warranted in non-aggressive
agitation. The ADWG definition criterion B allows
both agitation without aggression (excessive motor
activity) and with aggression (verbal aggression
and physical aggression). Investigators using this
definition of agitation should note which elements
of criterion B were met (e.g. excessive motor
activity, verbal aggression, or physical aggression).
Longitudinal comparison of studies will help
define the relationship between agitation and
aggression, and the ADWG definition will advance
understanding of this aspect of agitation.
This definition will be useful in the study of
psychosocial interventions and in clinical trials of
anti-agitation agents. The absence of a consensus
definition may have contributed to the lack of
activity in developing new therapies for agitation
with cognitive impairment; no agent has been
approved for treatment of this syndrome in spite of
extensive documentation of the disability associated
with agitation. Study entry would require that
the participants have agitation as defined by the
ADWG. A minimum baseline severity level on
an agitation scale would typically be required. An
outcome measure – usually an agitation measure
different from the one used to define entry severity –
would be used to compare baseline with end-of-
study scores for the active treatment and the placebo
(or active comparator) control group. It may be
useful to control for other behavioral features
such as mood changes or psychosis. The ADWG
definition could play a critical role in defining the
patient population for such trials.
The development of a provisional definition
of agitation is the first step in advancing a
research agenda for the definition. Validity studies
using other agitation assessments, reliability of the
application of the definition, usefulness in clinical
trials, usefulness in non-pharmacologic research,
and real-world application in clinical and healthcare
settings will lead to refinements and adjustments
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that will enhance the definition and advance the
study of neuropsychiatric syndromes in cognitive
impairment disorders.
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